The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

The transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases ...

Nuvectis Pharma, Inc. NVCT shares are trending on Monday. NVCT shares surged 19.61% during Monday’s regular trading session ...

Haisco will receive $40m upfront and may earn up to $1.4bn in additional milestone payments.

A research team at the Medical University of South Carolina reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that ...

Detailed price information for China Medical System Holdings Ltd (CHSYF) from The Globe and Mail including charting and trades.

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The complement inhibitors are the latest ...

Nuvectis Pharma Inc (NASDAQ:NVCT) shares gained 5. 7% in premarket trading on Monday after the company announced a licensing ...

SAN DIEGO -- Intravenous ravulizumab (Ultomiris) yielded clinically meaningful reductions in IgA nephropathy-related proteinuria in a small, mid-stage trial. The 43 patients treated with ravulizumab ...

(Yicai) June 23 -- Haisco Pharmaceutical Group's shares jumped after the drugmaker granted US' Nuvectis Pharma the exclusive ...

The FDA granted accelerated approval to iptacopan (Fabhalta) for primary immunoglobulin A (IgA) nephropathy, a rare progressive disease where the immune system attacks the kidneys, Novartis announced ...